CliffBio
biologic

Gazyva

obinutuzumab

Loss of exclusivityNovember 2025projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand nameGazyva
Active ingredientobinutuzumab
Strength1,000MG/40ML (25MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalNovember 2013
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Gazyva patent cliff — loss of exclusivity November 2025 | CliffBio